HIV CARE CONTINUUM & BEYOND

hiv care continuum & beyond logo

The HIV Care Continuum and Beyond (HIVCCB) white paper calls on Asian territories to reprioritise HIV and end the epidemic. The expert steering committee proposes 14 recommendations to help territories address four major challenge areas in Asia

Find out specific actions that you can take today.
See each country’s profile and progress towards 95-95-95 targets

Download the HIVCCB White Paper

English

简体中文

繁體中文

한국인

ไทย

Working together towards the 95-95-95 UNAIDS Targets

The UNAIDS Fast Track targets are still achievable if action is taken quickly. Rising to the challenge, the HIV Care Continuum & Beyond (HIVCCB) initiative was born with funding and support from ViiV Healthcare with the goal of developing actionable insights into the challenges and solutions to the HIV epidemic in Asia. It is led by a steering committee of experts on HIV in Asia including leading HIV academics, healthcare professionals, community organisations and patient advocates in China, Hong Kong SAR, Singapore, South Korea, Taiwan and Thailand.

This initiative is in partnership with the APCOM Foundation, the Institute of HIV Research and Innovation (IHRI), TREAT Asia/amfAR, Lourdes Association, Taiwan Love and Hope Association, and Love4One.

hiv care continuum & beyond

The HIVCCB’s inaugural white paper - a blueprint for ending HIV in Asia by 2030

In December 2022, the HIVCCB steering committee released a white paper that analysed the current HIV landscape in six key Asian territories and called for modern, community-led solutions to help end the long-running epidemic. Drawing on a broad multi-lingual literature review and consultation with HIV communities and experts across the six territories, the paper outlines 14 recommendations across four challenge areas to end HIV as a public health issue in Asia by 2030, improve care and enhance quality of life for people living with the disease in the region.

ViiV White paper
14 recommendations
ViiV White Paper Cover

Click here to watch the HIVCCB forum for launch of white paper

Partners

apcom
IHRI
Treat Asia amfAR
Taiwan Loudres Association
love4one
hope

White paper endorsers

LOVE logo
H.E.A.R.T logo
Taiwan AIDS Foundation logo

References:

  1. UNAIDS. (2022). Fact Sheet 2022. Https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
  2. Zhao, Y. (2021, November 30). Clinicalthought - HIV and aging: Asia-pacific - global perspectives - EACS 2021. Retrieved October 27, 2022, from https://www.clinicaloptions.com/hiv/conference-coverage/2021/eacs-2021/global-perspectives/ct8-asia-english/page-1#
  3. Putting Young Populations First - HIV and Young People from Key Populations in the Asia and Pacific Region 2022 (Rep.). (2022). Retrieved October 27, 2022, from UNAIDS website: https://www.aidsdatahub.org/sites/default/files/resource/unaids-2022-hiv-young-people-key-populations-ap-2022.pdf
  4. Bavinton, B. R., Pinto, A. N., Phanuphak, N., Grinsztejn, B., Prestage, G. P., Zablotska-Manos, I. B., ... & Orth, D. (2018) Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. The Lancet HIV, 5(8), e438-e447.

SUPPORTED BY:

ViiV Logo

NP-GBL-HVX-COCO-230006

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.